A Multinational Phase III Study of CS-8958 (MARVEL)
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to confirm the efficacy of CS-8958 administered as a
single inhaled low dose or single inhaled high dose by showing non-inferiority to oseltamivir
phosphate using the time to alleviation of influenza illness. For safety evaluation,
between-group comparisons will be made with regard to incidence of adverse events and other
safety measures.
In a secondary objective, the optimum dosage of CS-8958 for this indication will be evaluated
based on the efficacy and safety of single inhaled low or high dose.